For research use only. Not for therapeutic Use.
Rifaximin（Cat No.:A001202）is a broad-spectrum antibiotic derived from rifamycin, known for its effectiveness against gastrointestinal bacterial infections due to minimal absorption in the bloodstream. It works by inhibiting bacterial RNA synthesis, targeting pathogens within the gut while sparing beneficial flora. Rifaximin is widely used for treating traveler’s diarrhea, irritable bowel syndrome with diarrhea (IBS-D), and hepatic encephalopathy by reducing ammonia-producing bacteria. Its localized action in the intestines minimizes systemic side effects, making it a well-tolerated option for chronic or recurrent GI infections and disorders requiring prolonged treatment.
| Catalog Number | A001202 |
| CAS Number | 80621-81-4 |
| Synonyms | NA |
| Molecular Formula | C43H51N3O11 |
| Purity | ≥95% |
| Target | DNA Synthesis |
| Solubility | >39.3mg/mL in DMSO |
| Storage | 3 years -20C powder |
| IUPAC Name | [(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,36-tetrahydroxy-11-methoxy-3,7,12,14,16,18,22,30-octamethyl-6,23-dioxo-8,37-dioxa-24,27,33-triazahexacyclo[23.10.1.14,7.05,35.026,34.027,32]heptatriaconta-1(35),2,4,9,19,21,25(36),26(34),28,30,32-undecaen-13-yl] acetate |
| InChI | InChI=1S/C43H51N3O11/c1-19-14-16-46-28(18-19)44-32-29-30-37(50)25(7)40-31(29)41(52)43(9,57-40)55-17-15-27(54-10)22(4)39(56-26(8)47)24(6)36(49)23(5)35(48)20(2)12-11-13-21(3)42(53)45-33(34(32)46)38(30)51/h11-18,20,22-24,27,35-36,39,48-51H,1-10H3,(H,45,53)/b12-11+,17-15+,21-13-/t20-,22+,23+,24+,27-,35-,36+,39+,43-/m0/s1 |
| InChIKey | NZCRJKRKKOLAOJ-XRCRFVBUSA-N |
| SMILES | C[C@H]1/C=C/C=C(\C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)O[C@@](C4=O)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)/C |
| Reference | </br>1:The influence of rifaximin on diverticulitis rate and quality of life in patients with diverticulosis. Banasiewicz T, Francuzik W, Bobkiewicz A, Krokowicz Ł, Borejsza-Wysocki M, Paszkowski J, Studniarek A, Krokowicz P, Grochowalski M, Szczepkowski M, Lorenc Z.Pol Przegl Chir. 2017 Feb 28;89(1):22-31. doi: 10.5604/01.3001.0009.6012. PMID: 28522790 </br>2:A meta-analysis of the use of rifaximin to prevent travellers/’ diarrhoea. Ng QX, Ho CYX, Shin D, Venkatanarayanan N, Chan HW.J Travel Med. 2017 Sep 1;24(5). doi: 10.1093/jtm/tax025. PMID: 28498921 </br>3:Response to: Improvement of sleep architecture parameters in cirrhotic patients with recurrent hepatic encephalopathy with the use of rifaximin: hepatic encephalopathy in association with zolpidem. Nevo ON, Brinker AD, Diak IL, Kortepeter CM.Eur J Gastroenterol Hepatol. 2017 May 3. doi: 10.1097/MEG.0000000000000894. [Epub ahead of print] No abstract available. PMID: 28471831 </br>4:Diagnosis of symptomatic uncomplicated diverticular disease and the role of Rifaximin in management. Maconi G.Acta Biomed. 2017 Apr 28;88(1):25-32. doi: 10.23750/abm.v88i1.6360. PMID: 28467330 </br>5:Rifaximin in Non-Alcoholic Steatohepatitis: An Open-Label Pilot Study. Cobbold JFL, Atkinson S, Marchesi JR, Smith A, Wai SN, Stove J, Shojaee-Moradie F, Jackson N, Umpleby AM, Fitzpatrick J, Thomas EL, Bell JD, Holmes E, Taylor-Robinson SD, Goldin RD, Yee MS, Anstee QM, Thursz MR.Hepatol Res. 2017 Apr 20. doi: 10.1111/hepr.12904. [Epub ahead of print] PMID: 28425154 </br>6:Retrospective comparison of long-term ten-day/month rifaximin or mesalazine in prevention of relapse in acute diverticulitis. Festa V, Spila Alegiani S, Chiesara F, Moretti A, Bianchi M, Dezi A, Traversa G, Koch M.Eur Rev Med Pharmacol Sci. 2017 Mar;21(6):1397-1404. PMID: 28387885 Free Article</br>7:Rifaximin in the Treatment of Patients With Diarrhea-Predominant Irritable Bowel Syndrome. Dai C, Jiang M, Sun MJ.Gastroenterology. 2017 May;152(6):1629-1630. doi: 10.1053/j.gastro.2016.09.068. Epub 2017 Apr 1. No abstract available. PMID: 28376323 </br>8:The impact of rifaximin in the prevention of bacterial infections in cirrhosis. Mariani M, Zuccaro V, Patruno SF, Scudeller L, Sacchi P, Lombardi A, Vecchia M, Columpsi P, Marone P, Filice G, Bruno R.Eur Rev Med Pharmacol Sci. 2017 Mar;21(5):1151-1158. PMID: 28338174 Free Article</br>9:Susceptibility to rifaximin and other antimicrobials of bacteria isolated in patients with acute gastrointestinal infections in Southeast Mexico. Novoa-Farias O, Frati-Munari AC, Peredo MA, Flores-Juárez S, Novoa-García O, Galicia-Tapia J, Romero-Carpio CE.Rev Gastroenterol Mex. 2017 Mar 12. pii: S0375-0906(17)30021-6. doi: 10.1016/j.rgmx.2016.10.006. [Epub ahead of print] English, Spanish. PMID: 28298258 Free Article</br>10:Rifaximin (Xifaxan) for Irritable Bowel Syndrome. Karuppiah S, Pomianowski K.Am Fam Physician. 2017 Feb 15;95(4):258-259. No abstract available. PMID: 28290635 |
